In Vivo Toxicology Market Report 2026

The in vivo toxicology market size has grown strongly in recent years. It will grow from $5.61 billion in 2025 to $6 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to limited availability of standardized animal models, reliance on manual laboratory procedures, growing pharmaceutical R&D activities, increasing prevalence of chronic disease studies, adoption of basic imaging and analytical instruments.

The in vivo toxicology market size is expected to see strong growth in the next few years. It will grow to $7.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of genetically modified organisms for targeted studies, integration of automated and high-throughput screening systems, rising CRO outsourcing for toxicology testing, advancements in in vivo imaging and monitoring technologies, increasing focus on alternative models and reduction of animal testing. Major trends in the forecast period include growing adoption of rodent and non-human primate models, rising demand for advanced toxicology assay kits and reagents, expansion of immunotoxicity and genotoxicity testing services, increasing use of automated liquid handling and imaging systems, enhanced regulatory compliance and ethical standards in animal testing.

The growing number of drug discoveries is expected to drive the expansion of the in vivo toxicology market in the coming years. Drug discovery involves the scientific identification and design of new compounds that could serve as treatments or preventive measures for various diseases. Advances in biotechnology have significantly accelerated this process by improving the understanding of disease mechanisms and enabling the development of more targeted therapies. In vivo toxicology plays a crucial role in drug discovery by assessing the safety, tolerability, and potential adverse effects of investigational compounds in whole organisms. It helps identify dose-limiting toxicities and guides formulation and dosing strategies before clinical development. For example, in November 2024, the Patented Medicine Prices Review Board (PMPRB), a Canada-based government agency, reported that over 12,000 new medicines were in clinical trials in 2023, up from around 9,000 in 2022, with oncology accounting for 33% of the pipeline and infectious and central nervous system diseases representing 13% and 12%, respectively. This indicates that the increasing number of drug discoveries is fueling growth in the in vivo toxicology market.

Key players in the in vivo toxicology market are focusing on the development of advanced solutions, such as secure cloud-based real-time data platforms, to streamline study management and accelerate decision-making. These platforms allow researchers and clients to access toxicology study data, milestones, planning tools, and documents remotely and securely, enhancing collaboration and transparency. For instance, in March 2023, Charles River Laboratories International Inc., a U.S.-based contract research organization, launched Apollo, a secure cloud-based platform that provides real-time access to toxicology study data. Designed to support in vivo general toxicology studies, Apollo offers tools for data visualization, planning, and milestone tracking, enabling faster and more informed decision-making. The platform also helps streamline project planning and budget estimation throughout the drug development process. By digitizing toxicology workflows, Apollo improves precision, efficiency, and collaboration in in vivo research.

In October 2023, ETAP Lab SAS, a France-based preclinical contract research organization (CRO), acquired Syncrosome SAS, a France-based preclinical CRO specializing in in vivo pharmacology for cardiopulmonary pathologies. Through this acquisition, ETAP Lab SAS aims to enhance its cardiovascular and pulmonary disease model capabilities and expand its service portfolio. Syncrosome SAS provides in vivo R&D services in cardiology and pneumology.

Major companies operating in the in vivo toxicology market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Sigma-Aldrich Co. LLC, Eurofins Scientific SE, Agilent Technologies Inc., WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Jubilant Life Sciences Limited, Evotec SE, The Jackson Laboratory, Inotiv Inc., Transcure Bioservices Pvt. Ltd.

North America was the largest region in the in-vivo toxicology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vivo toxicology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in vivo toxicology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the in vivo toxicology market by increasing the cost of imported laboratory instruments, consumables, and specialized reagents. Segments such as imaging systems, flow cytometers, and animal monitoring equipment are most affected, with regions like Asia-Pacific including China and India facing significant import duties. This has led to higher operational costs and supply chain disruptions. On the positive side, tariffs have encouraged local manufacturing of consumables and instruments, fostering innovation and domestic production capacity growth.

The in vivo toxicology market research report is one of a series of new reports that provides in vivo toxicology market statistics, including in vivo toxicology industry global market size, regional shares, competitors with a in vivo toxicology market share, detailed in vivo toxicology market segments, market trends and opportunities, and any further data you may need to thrive in the in vivo toxicology industry. This in vivo toxicology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In vivo toxicology is a field of toxicology that examines the effects of chemical, biological, or physical agents on living organisms under controlled conditions. This approach emphasizes understanding how substances interact with complex biological systems, allowing the evaluation of physiological, biochemical, and behavioral changes within an intact organism.

The main products in in vivo toxicology include consumables and instruments. In vivo toxicology consumables consist of materials such as reagents, animal feed, and sample containers used in experiments on live organisms to evaluate the safety or toxicity of substances. This field involves various types of testing, including chronic toxicity, sub-chronic toxicity, sub-acute toxicity, and acute toxicity testing, and employs multiple methodologies such as in vivo animal models, genetically modified organisms, non-human primate studies, rodent models, and larger mammals. It is applied to areas such as immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and others, and serves a range of end users including pharmaceutical companies, biosimilar manufacturers, contract research organizations (CROs), academic and research institutions, and biotechnology firms.

The in vivo toxicology market consists of revenues earned by entities by providing services such as neurotoxicity assessment, dermal toxicity testing, ocular toxicity testing, and local tolerance testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vivo toxicology market also includes sales of anesthesia systems, telemetry devices, blood collection and sampling tools, drug delivery systems, and environmental control equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.